

## Special Issue

# Application of Animal Models and New Therapeutic Approaches in Neurological Diseases

### Message from the Guest Editors

The aim of this Research Topic is to discover and integrate new, state-of-the-art preclinical models that can contribute to minimize current limitations from the classic animal models available for neurological diseases. Furthermore, new therapeutic strategies aiming to attenuate the symptoms and/or the pathology mechanisms of neurological diseases are also welcome. Evidence from preclinical studies, as well as meta-analyses or reviews assembling firm evidence on this theme, will also contribute to our understanding.

### Guest Editors

Dr. Ana Carolina Pinheiro Campos

Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Dr. Daniel Oliveira Martins

Hospital Sírio-Libanês, São Paulo, Brazil

### Deadline for manuscript submissions

closed (30 April 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/173508](https://mdpi.com/si/173508)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).